Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,743,161
  • Shares Outstanding, K 80,666
  • Annual Sales, $ 1,140 K
  • Annual Income, $ -88,040 K
  • EBIT $ -180 M
  • EBITDA $ -185 M
  • 60-Month Beta 1.32
  • Price/Sales 1,983.11
  • Price/Cash Flow N/A
  • Price/Book 6.52

Options Overview Details

View History
  • Implied Volatility 75.58% (+2.82%)
  • Historical Volatility 44.64%
  • IV Percentile 58%
  • IV Rank 25.63%
  • IV High 147.24% on 04/22/25
  • IV Low 50.89% on 08/18/25
  • Expected Move (DTE 18) 6.31 (10.92%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 36
  • Volume Avg (30-Day) 1,428
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 30,702
  • Open Int (30-Day) 11,964
  • Expected Range 51.45 to 64.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.67
  • Number of Estimates 4
  • High Estimate -0.62
  • Low Estimate -0.73
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -48.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.51 +19.07%
on 02/05/26
60.00 -3.73%
on 02/25/26
+3.42 (+6.29%)
since 02/02/26
3-Month
37.01 +56.07%
on 12/17/25
60.00 -3.73%
on 02/25/26
+16.39 (+39.62%)
since 12/02/25
52-Week
14.80 +290.27%
on 04/09/25
60.00 -3.73%
on 02/25/26
+31.90 (+123.36%)
since 02/28/25

Most Recent Stories

More News
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination...

CGON : 57.76 (-1.77%)
CG Oncology to Present at the TD Cowen 46th Annual Health Care Conference

IRVINE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating...

CGON : 57.76 (-1.77%)
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 1.0200 (-9.73%)
CGON : 57.76 (-1.77%)
TAK : 18.44 (-1.65%)
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC

- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial...

CGON : 57.76 (-1.77%)
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference

IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 57.76 (-1.77%)
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Applications for the fellowship are due on...

CGON : 57.76 (-1.77%)
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC demonstrates...

CGON : 57.76 (-1.77%)
CG Oncology Announces New Board Member and Board Transition

- Appoints Accomplished Life Sciences Executive Christina Rossi to its Board of Directors - IRVINE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical...

CGON : 57.76 (-1.77%)
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 26th Annual Meeting

IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing...

CGON : 57.76 (-1.77%)
CG Oncology Reports Third Quarter 2025 Financial Results and Provides Business Updates

Initiated rolling Biologics License Application (BLA) submission to U.S. FDA for cretostimogene monotherapy in high-risk (HR) BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) Demonstrated...

CGON : 57.76 (-1.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 62.70
2nd Resistance Point 61.05
1st Resistance Point 59.41
Last Price 57.76
1st Support Level 56.11
2nd Support Level 54.46
3rd Support Level 52.82

See More

52-Week High 60.00
Last Price 57.76
Fibonacci 61.8% 42.73
Fibonacci 50% 37.40
Fibonacci 38.2% 32.07
52-Week Low 14.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar